RxDoctor Payments Data

Jonathan Hunter, MD

Family Medicine · Alexandria, LANPI 1619969532

Payments from drug & device makers

$10,940in general payments, 2019–2025

Across 744 payments — averaging $14.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$1K
  • GSK$968
  • Lilly USA, LLC$706
  • Amgen$609
  • AstraZeneca$599
  • plus $4K from 46 others

What the payments were for

  • Food & beverage$10,940100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,940 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$274,612
Medicare patients
571
Services billed
6,563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide146$165,546
OzempicSemaglutide151$150,656
JardianceEmpagliflozin80$67,011
EliquisApixaban83$55,225
TrulicityDulaglutide46$53,689
WegovySemaglutide26$33,508
XareltoRivaroxaban56$33,045
FarxigaDapagliflozin Propanediol34$29,957
JanuviaSitagliptin Phosphate29$28,854
RybelsusSemaglutide25$24,189
LinzessLinaclotide38$21,900
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$14,691
VascepaIcosapent Ethyl27$14,215
MyrbetriqMirabegron13$8,323
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$7,726

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$706$219,235192 claims
Novo NordiskOzempic, Wegovy, Rybelsus$1,128$208,353202 claims
Boehringer IngelheimJardiance$153$67,01180 claims
PfizerEliquis$376$55,22583 claims
Johnson & JohnsonXarelto$75$33,04556 claims
AstraZenecaFarxiga$599$29,95734 claims
MerckJanuvia$128$28,85429 claims
AbbVieLinzess, Synthroid$2,777$24,50474 claims
Astellas Pharma US IncMyrbetriq$140$8,32313 claims
GSKTrelegy Ellipta$968$7,72613 claims
NovartisEntresto$38$5,47613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Alexandria

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →